Total: $173.18M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@


Allos Therapeutics Inc. (ALTH)

Private placement of stock and warrants

5.17S and 1.7W

$12

Allos sold about 5.17M shares at $2.32 each, and issued 1.7M warrants that can be exercised until November 2007 at $3.14 per share; SG Cowen Securities Corp. was placement agent (11/20)

Aradigm Corp. (ARDM)

Private placement of stock

7.5S

$13.5

Aradigm sold about 7.5M shares at $1.80 each, a discount of about 16%; SG Cowen Securities Corp. was placement agent for the deal, which included many of the investors that took part in a May 2003 financing (11/10)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Private placement of stock and warrants

5.38S and 3.23W

$8

Avanir entered agreements to raise $8M by selling about 5.38M shares at $1.49 each and warrants to purchase up to 3.23M shares at $1.75; Rodman & Renshaw was placement agent (11/26)

Cepheid Inc. (CPHD)

Private placement of stock

0.556S

$2

The institutional investors that purchased $10M in stock in August exercised an option on another 555,556 additional shares, bringing in another $2M; UBS Securities was financial adviser (11/10)

ConjuChem Inc. (Canada; TSE:CJC)

Bought-deal financing

6S

C$24.9
(US$18.7)

ConjuChem raised the money in a bought-deal financing; the total includes the exercise of the overallotment option y Orion Securities Inc., Sprott Securities Inc. and BMO Nesbitt Burns Inc. (11/3)

Cytogen Corp. (CYTO)

Private placement of stock

1.86S

$20.5

Cytogen sold the shares at $11 each to institutional investors under an effective shelf registration statement (11/7)

Enhance Biotech Inc. (OTC BB:EBOI)

Private placement of stock and warrants

ND

$2

Details on the financing were not disclosed, although Enhance said it could get another $2M if it meets development milestones (11/3)

EntreMed Inc. (ENMD)

Private placement of stock and warrants

5.25S and 0.79W

$22.3

EntreMed placed the shares and warrants with undisclosed institutional investors; the shares were priced at $4.25 and the warrants are exer- cisable at $5 per share; Rodman & Renshaw was placement agent (11/3)

Genaera Corp. (GENR)

Registered direct offering

2.05S

$8.5

Genaera accepted subscriptions from institutional investors in a direct offering of shares priced at $4.15 each, the Nov. 10 closing price; Fortis Securities Inc. was placement agent (11/11)

Hemosol Inc. (Canada; HMSL)

Sale of special warrants

7.84W

$5.88

Hemosol sold the warrants at $0.75 apiece; each special warrant entitles the holder to one common share and one-half of a warrant that in full can be exercised for one share at 90 cents for three years (11/28)

Inflazyme Pharmaceuticals Inc. (Canada; TSE:IZP)

Bought-deal financing

13.65S

C$15
(US$11.5)

Inflazyme sold 13.65M shares at C$1.10 per share; underwriters Orion Securities Inc. and RBC Capital Markets have an option to purchase up to 2.05M additional shares to cover overallotments (11/25)

InSite Vision Inc. (AMEX:ISV)

Assumption of redeemable debentures

N/A

$0.5

InSite received the second tranche of a $1M interim funding from an institutional investor, the first part of which was received in September; J.P. Turner & Co. Ltd. was financial representative (11/12)

Introgen Therapeutics Inc. (INGN)

Private placement of stock

2.86S

$20

Introgen sold the shares at $7 each from a registration statement for a sale of up to $100M in stock; SG Cowen Securities Corp. was placement agent (11/26)

Keryx Biopharmaceuticals Inc. (KERX)

Private placement of stock and warrants

3.5S and 0.7W

$15

Keryx sold 3.5M shares at $4.25 each along with about 700,000 five-year warrants exercisable at $6 per share; Rodman & Renshaw was placement agent (11/18)

Manhattan Pharmaceuticals Inc. (OTC BB:MHHT)

Private placement of convertible preferred stock

1S

$10

Manhattan sold 1M shares of Series A convertible preferred stock at $10 each; the stock can be converted into common shares at $1.10 per share; the deal was completed by Maxim Group LLC and Paramount Capital Inc. (11/10)

Neoprobe Corp. (OTC BB:NEOP)

Private placement of stock and warrants

12.2S and 6.1W

$2.8

Neoprobe sold 12.2M shares at 23 cents per share and issued five-year Series R warrants to purchase 6.1M shares at 28 cents each; institutional investors and high-net-worth individuals participated (11/17)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available, applicable or reported; ND = Not disclosed.

AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments